PHARMACEUTICAL 2022

Alnylam Pharmaceuticals INC
Rank 383 of 471



PHARMACEUTICAL 2022

Alnylam Pharmaceuticals INC
Rank 383 of 471

The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 13% points.The greatest weakness of Alnylam Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 135% points.

The company's Economic Capital Ratio, given in the ranking table, is 154%, being 121% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	2,808,576
Cost of Goods Sold	115,005
Intangible Assets	0
Liabilities, Current	695,710
Liabilities, Non-Current	532,670
Other Assets	332,770
Other Compr. Net Income	10,363
Other Expenses	25,819
Other Liabilities	1,826,721
Other Net Income	-143,492
Other Revenues	844,287
Property and Equipment	501,958
Research and Development	792,156
Selling, General and Administrative Expense	620,639

Output Variable	Value in 1000 USD
Assets	3,643,304
Liabilities	3,055,101
Expenses	1,553,619
Revenues	844,287
Stockholders Equity	588,203
Net Income	-852,824
Comprehensive Net Income	-847,642
BaseVar	4,625,083
ECR before LimitedLiability	13%
Economic Capital Ratio	154%